All In Biotech

Drug Trial Radar · NCT04637529

Efficacy and Safety of S (+) - Ibuprofen in Osteoarthritis Pain

National, Multicentre, Randomized, Double-blind, Double-dummy Phase II Clinical Trial to Evaluate the Efficacy and Safety of S (+) - Ibuprofen for Pain Control in Individuals With Osteoarthritis

Last checked: Nov 20, 2026Latest source record: Sep 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 176 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

176

Actual

Start

Aug 5, 2022

Primary completion

Jun 30, 2023

Study completion Jun 30, 2023

Sponsor

Lead sponsor
Apsen Farmaceutica S.A.Industry
Sponsor type
Industry
First posted
Nov 19, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy of S (+) - ibuprofen compared to an active treatment for pain control in individuals diagnosed with osteoarthritis.

Conditions

  • Osteoarthritis

Interventions

  • S (+) - IbuprofenDrug

    S (+) - Ibuprofen + placebo of Ibuvix®

  • Ibuvix® - ibuprofenDrug

    Ibuvix® + placebo of S(+) - Ibuprofen

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean reduction of pain measured by the WOMAC Osteoarthritis Index (pain)Time frame: Baseline (day 0) and Week 4 (day 28)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Apsen Farmacêutica S.A.

    São Paulo, São Paulo, Brazil

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.